Results 141 to 150 of about 45,210 (266)

Clozapine Alone versus Clozapine and Risperidone for Refractory Schizophrenia [PDF]

New England Journal of Medicine, 2006
ANIL YAĞCIOĞLU, AYŞE ELİF, Akdede, BBK, Meltzer, HY   +2 more
openaire   +4 more sources

Gq Signaling in Microglia Triggers Interferon Responses and Improves Outcome After Ischemic Stroke

Glia, Volume 74, Issue 10, October 2026.
Chemogenetic activation of Gq signaling in microglia ahead of ischemic stroke reduces infarct size in mice. Seven days after stroke, Gq‐primed microglia in the penumbra show enhanced interferon responses, altered branching patterns, and reduced phagocytosis.
Lynn Bitar, Marie‐Luise Brehme, Charlotte Oldenburg, Sara Isla Cainzos, Michael G. Kaul, Tobias Mummert, Malte Borggrewe, Thomas G. Oertner, Tim Magnus   +8 more
wiley   +1 more source

Complications of clozapine cessation in the context of chemotherapy-related neutropenia-a case report. [PDF]

Front Oncol
Sweeney C, Rush G, O'Dwyer S, Mac Eochagain C, Plunkett R.   +4 more
europepmc   +1 more source

Agomelatine as augmentation therapy with second‐generation antipsychotics for negative symptoms of schizophrenia: An open‐label randomised clinical trial and electroencephalogram‐derived model for treatment response prediction

General Psychiatry, Volume 39, Issue 5, October 2026.
ABSTRACT Background Negative symptoms are a core diagnostic domain of schizophrenia that affect functional outcomes and remain difficult to treat. Agomelatine, a novel antidepressant with melatonin receptor agonism and serotonin 2C receptor antagonism, may have therapeutic potential.
Wanyan Zhou, Fei Liang, Nizhe Chen, Yao Zhang, Xiaoxiao Wang, Xin Li, Daofeng Lu, Fang Guo, Yuan Yao, Jiayu Zhu, Chengjia Shen, Chongze Wang, Peiyun Zhang, Lilan Zhao, Ying Wang, Jinyu Han, Wei Li, Haisu Wu, Peijuan Wang, Qi Yan, Ping Zhang, Qinyu Lv, Zhenghui Yi   +22 more
wiley   +1 more source

Cariprazine Augmentation and Sustained Remission of Physical Aggression in Clozapine-Treated Treatment-Resistant Schizophrenia: A Case Report. [PDF]

Case Rep Psychiatry
Leijala J, Mustonen A.
europepmc   +1 more source

Informing Your Future Clozapine Patients of the Mortality Risk: Fear of Agranulocytosis vs. Pharmacovigilance Fatal Outcomes. [PDF]

Actas Esp Psiquiatr
de Leon J, Ruan CJ, Schoretsanitis G, Sanz EJ, De Las Cuevas C.   +4 more
europepmc   +1 more source

Brown Adipose Tissue: Molecular Mechanisms of Regulation, Physiological Functions, and Therapeutic Targets

MedComm, Volume 7, Issue 10, October 2026.
This review systematically covers three core dimensions of brown adipose tissue (BAT): multilayered regulatory mechanisms governing brown adipocyte differentiation and phenotypic identity, physiological functions and signaling pathways in mediating thermogenesis and systemic metabolic crosstalk between BAT and multiple organs, and emerging clinical in ...
Xiaoli Deng, Yuanyuan Shen, Ying Sun, Lu Lu, Chongkui Sun   +4 more
wiley   +1 more source

Clozapine Induced Pityriasiform Eruption

, 1997
Clozapine is a new atypical antipsychotic drug.
Bhatia M S, Choudhary Sandeep, Khanna Sanjay, Agrawal Pradeep   +3 more
core  

Placebo Effect in Levodopa‐Induced Dyskinesia: A Systematic Review and Meta‐Analysis

Movement Disorders Clinical Practice, Volume 13, Issue 10, Page 2365-2378, October 2026.
Abstract Background Levodopa‐induced dyskinesia (LID) is a complication of Parkinson's disease (PD) treatment. While the placebo effect is a known component in PD clinical trials, its specific magnitude in the context of LID is not well characterized.
Luiz Vinicius Silva Correa, Alexandre Martins do Nascimento, Bruno Lopes Santos‐Lobato, Henry Mauricio Chaparro‐Solano, Ignacio Fernandez Mata, Vitor Tumas   +5 more
wiley   +1 more source

Revisiting clozapine-induced mania: When a case report informs clinical decisions. [PDF]

Dusunen Adam
Cholette-Tétrault S, Bakhshi M.
europepmc   +1 more source